Good evening.

You know that AstraZeneca‘s vaccine is currently in the final stages of the approval process with the European Medicines Agency.

If all requirements are met, the European Medicines Agency could recommend market authorisation by the end of this week.

But there is a problem on the supply side.

Last Friday, the company AstraZeneca surprisingly informed the Commission and the European Union Member States that it intends to supply considerably fewer doses in the coming weeks than agreed and announced.

This new schedule is not acceptable to the European Union.